Auro Laboratories Limited
Auro Laboratories Limited Fundamental Analysis
Auro Laboratories Limited (AUROLAB.BO) shows weak financial fundamentals with a PE ratio of 51.02, profit margin of 11.35%, and ROE of 7.49%. The company generates $0.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 36.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze AUROLAB.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakAUROLAB.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateAUROLAB.BO shows balanced valuation metrics.
Growth Score
ModerateAUROLAB.BO shows steady but slowing expansion.
Financial Health Score
WeakAUROLAB.BO carries high financial risk with limited liquidity.
Profitability Score
WeakAUROLAB.BO struggles to sustain strong margins.
Key Financial Metrics
Is AUROLAB.BO Expensive or Cheap?
P/E Ratio
AUROLAB.BO trades at 51.02 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, AUROLAB.BO's PEG of 0.35 indicates potential undervaluation.
Price to Book
The market values Auro Laboratories Limited at 3.79 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 13.56 times EBITDA. This signals the market has high growth expectations.
How Well Does AUROLAB.BO Make Money?
Net Profit Margin
For every $100 in sales, Auro Laboratories Limited keeps $11.35 as profit after all expenses.
Operating Margin
Core operations generate 18.21 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.49 in profit for every $100 of shareholder equity.
ROA
Auro Laboratories Limited generates $2.92 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Auro Laboratories Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Auro Laboratories Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
AUROLAB.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
51.02
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.35
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.79
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.79
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.008
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.61
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How AUROLAB.BO Stacks Against Its Sector Peers
| Metric | AUROLAB.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 51.02 | 27.91 | Worse (Expensive) |
| ROE | 7.49% | 687.00% | Weak |
| Net Margin | 11.35% | -45285.00% (disorted) | Strong |
| Debt/Equity | 1.01 | 0.33 | Weak (High Leverage) |
| Current Ratio | 0.61 | 2795.76 | Weak Liquidity |
| ROA | 2.92% | -13557.00% (disorted) | Weak |
AUROLAB.BO outperforms its industry in 1 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Auro Laboratories Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation